香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 持續關連交易 續簽採購框架協議 續簽採購框架協議 於 2025 年 10 月 30 日，本公司與永發印務訂立期限自 2026 年 1 月 1 日起至 2026 年 12 月 31 日止為 期一年的採購框架協議，據此，永發印務集團將向本集團繼續提供藥品的印刷包裝材料。 香港上市規則之含義 鑒於上實集團為本公司及上海實業之控股股東，永發印務為上海實業之間接非全資附屬公司，永發 印務屬於本公司於上市規則第 14A.07 條項下之關連人士。因此，根據上市規則第 14A 章，於採購框 架協議項下與永發印務集團擬進行之交易將構成本公司的持續關連交易。 茲提述本公司日期為 2024年 10月 30日的公告，內容有關現有採購框架協議 ...

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海醫藥集團股份有限公司 | | 股份代號 | 02607 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月之中期股息 | | 公告日期 | 2025年10月31日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 10 股 1.2 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 | 有待公佈 ...

证券代码：601607 证券简称：上海医药 编号：临 2025-097 上海医药集团股份有限公司 第八届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海医药集团股份有限公司（以下简称"本公司"）第八届监事会第十四次 会议（以下简称"本次会议"）于 2025 年 10 月 30 日在上海市太仓路 200 号上海 医药大厦 1101 会议室召开，参加本次会议应到监事 3 名，实到监事 3 名，符合 《中华人民共和国公司法》和本公司章程关于监事会召开法定人数的规定。本次 会议由徐有利监事长主持。本次会议审议通过以下议案： 一、《2025 年第三季度报告》 1、公司 2025 年第三季度报告的编制和审议程序符合法律、法规、公司章程 和公司内部管理制度的各项规定； 2、公司 2025 年第三季度报告的内容和格式符合中国证监会和上海证券交易 所的各项规定，所包含的信息真实地反映了公司 2025 年前三季度的经营管理和 财务状况等事项； 二、《2025 年半年度利润分配预案》 本 公 司 2025 年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 公告 建議 2025 年半年度利潤分配方案 上海醫藥集團股份有限公司（「本公司」）於2025年10月30日召開第八屆董事會（「董事會」）第 25次會議審議通過了《2025年半年度利潤分配預案》。董事會謹此宣佈，本公司2025年半年度擬以實 施權益分派股權登記日登記的總股本為基數分配利潤。有關股權登記日的具體日期將由本公司另行公 佈確定。本次利潤分配方案（「利潤分配方案」）如下： 本公司2025年半年度實現合併歸屬於上市公司股東的淨利潤人民幣4,458,864,876.61元（未經審計）， 擬以截至2025年6月30日總股本3,708,361,809股為基數，向全體股東每10股派發現金紅利人民幣1.20元 （含稅），合 ...

上海医药集团股份有限公司（以下简称"本公司"或"上海医药"或"本集 团"）第八届董事会第二十五次会议（以下简称"本次会议"）于 2025 年 10 月 30日在上海市太仓路200号上海医药大厦1101会议室以现场结合通讯方式召开。 本次会议应到董事九名，实到董事九名，符合《中华人民共和国公司法》和本公 司章程关于董事会召开法定人数的规定。本次会议由杨秋华董事长主持，监事和 部分高级管理人员列席本次会议。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 证券代码：601607 证券简称：上海医药 公告编号：临2025-096 上海医药集团股份有限公司 第八届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 1、《2025 年第三季度报告》 本议案已提交公司第八届董事会审计委员会第十四次会议审议通过，同意提 交董事会审议。 表决结果：赞成 9 票，反对 0 票，弃权 0 票 2、《关于与永发印务有限公司续签<采购框架协议>暨日常关联/持续关连交 易的议案》 本议案已 ...

证券代码：601607 证券简称：上海医药 编号：临2025-099 重要内容提示： 上海医药集团股份有限公司 2025 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、利润分配方案内容 经董事会决议，公司拟以实施权益分派股权登记日登记的总股本为基数实施 2025 年半年度利润分配。本次利润分配方案如下： 本 公 司 2025 年 半 年 度 实 现 合 并 归 属 于 上 市 公 司 股 东 的 净 利 润 4,458,864,876.61 元（未经审计），拟以截至 2025 年 6 月 30 日总股本 3,708,361,809 股为基数，向全体股东每 10 股派发现金红利 1.20 元（含税），合计拟派发现金 红利总额为 445,003,417.08 元（含税），占 2025 年半年度合并归属于上市公司 股东的净利润的 9.98%。2025 年半年度不进行资本公积金转增股本。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本发生变 动的，公司拟以实施权益分派股权登记日的总股 ...

Financial Performance - For the first nine months of 2025, Shanghai Pharmaceuticals achieved a revenue of RMB 215.07 billion, representing a year-on-year growth of 2.60%[11] - The net profit attributable to shareholders for the same period was RMB 5.147 billion, a year-on-year increase of 26.96%, primarily due to a one-time special gain from changing accounting treatment for a joint venture[11] - The company's total profit for the period was CNY 1.48 billion, a decrease of 18.94% compared to the previous year[22] - The net profit attributable to shareholders was CNY 688.20 million, down 38.13% year-on-year[22] - The company's total profit for the first three quarters was ¥8.30 billion, up from ¥6.64 billion, reflecting an increase of approximately 25%[38] - Net profit for the first three quarters of 2025 was ¥5.99 billion, compared to ¥5.02 billion in 2024, marking an increase of approximately 19.2%[39] - The basic earnings per share rose to ¥1.39 from ¥1.09, indicating a growth of about 27.5%[39] Research and Development - Research and development expenses for the first nine months amounted to RMB 1.729 billion, accounting for 9.52% of the pharmaceutical manufacturing revenue[12] - The company has 57 new drug candidates in clinical trials, including 45 innovative drugs, with significant progress in various projects[12] - The BCD-085 project, an innovative monoclonal antibody, has submitted a new drug application for ankylosing spondylitis during the reporting period[12] - The company completed patient enrollment for the Phase III clinical trial of the traditional Chinese medicine product, Shenqi Sharuang Wan, aimed at treating cervical spondylotic myelopathy[13] - Research and development expenses were reported at ¥1.52 billion, slightly down from ¥1.62 billion, indicating a decrease of about 6.5%[38] - Research and development expenses decreased to CNY 270,894,446.73 in 2025 from CNY 419,246,826.18 in 2024, reflecting a reduction of approximately 35.3%[49] Business Segments - The company's pharmaceutical business achieved a revenue of CNY 73.48 billion in the current reporting period, representing a year-on-year increase of 4.65%[22] - The innovative drug business generated sales of CNY 40.7 billion, with a year-on-year growth of over 25%[19] - The import agency business reported sales of CNY 27.6 billion, reflecting a year-on-year increase of over 14%[19] - The company has 51 products in the rare disease treatment field, covering 67 rare disease conditions[18] - The company is actively participating in building a rare disease prevention and treatment ecosystem, enhancing drug accessibility[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 236.75 billion, an increase of 7.02% from the previous year[22] - The company's current assets totaled RMB 183.93 billion, up from RMB 171.82 billion in the previous year, indicating a year-over-year increase of about 7.1%[33] - The total liabilities reached RMB 147.12 billion, compared to RMB 137.47 billion in the previous year, reflecting an increase of approximately 7.3%[35] - The company's cash and cash equivalents stood at RMB 36.73 billion, slightly up from RMB 35.74 billion, showing a growth of about 2.8%[33] - The total equity of the company reached RMB 89.62 billion, an increase from RMB 83.74 billion, representing a growth of about 7.5%[35] - The total liabilities increased to approximately $27.4 billion in 2025 from $25.8 billion in 2024, suggesting a rise in financial obligations[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,942[28] - The top ten shareholders collectively hold 1,427,235,837 shares, accounting for 38.487% of the total share capital[30] - HKSCC NOMINEES LIMITED is the largest shareholder with 918,240,949 shares, representing 24.761% of the total[28] - Shanghai Pharmaceutical (Group) Co., Ltd. holds 716,516,039 shares, which is 19.322% of the total[28] - The total share capital of the company at the end of the reporting period was 3,708,361,809 shares, including 2,789,289,105 A shares and 919,072,704 H shares[30] Cash Flow and Investments - Cash flow from operating activities generated a net amount of ¥2.35 billion, down from ¥2.78 billion in the previous year, a decrease of approximately 15.4%[41] - Cash inflow from investment activities significantly increased to ¥52.81 billion, compared to ¥19.35 billion in the same period last year, representing a growth of approximately 173.5%[41] - The company reported an investment income of ¥3.37 billion, a substantial increase from ¥343.49 million in the previous year[38] - The cash flow from operating activities showed a net outflow of CNY -391,042,716.21 in 2025, worsening from CNY -224,559,735.50 in 2024[53] - The cash and cash equivalents at the end of the period were CNY 6,980,854,073.85 in 2025, down from CNY 8,234,133,720.99 in 2024, indicating a decrease of approximately 15.2%[54] Corporate Recognition and ESG - Shanghai Pharmaceuticals has been recognized as one of the top ten enterprises in the "2024 Annual China Pharmaceutical Industry Main Business Revenue Top 100" list[11] - The MSCI ESG rating for the company has been upgraded to AA, reflecting its strong performance in environmental, social, and governance aspects[11]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone in its product development [1] Group 1: Product Approval - The sustained-release tablet of Bromidespasm has been granted a drug registration certificate by the National Medical Products Administration [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - Shanghai Pharmaceuticals submitted the registration application for this drug in March 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 16.09 million in research and development for this drug as of the date of the announcement [1]

Policy Developments - The "14th Five-Year Plan" emphasizes accelerating the construction of a Healthy China, implementing a health-first development strategy, and enhancing public health capabilities [2] - The plan aims to improve the healthcare system, promote the integration of traditional Chinese and Western medicine, and support the development of innovative drugs and medical devices [2] Drug and Device Approvals - Shanghai Pharmaceuticals' bromide pyridostigmine sustained-release tablets have received production approval from the National Medical Products Administration, which is expected to enhance market share and competitiveness [3] - The company has invested approximately RMB 16.009 million in the research and development of this drug [3] Financial Reports - Fosun Pharma reported a 26% year-on-year increase in net profit for the first three quarters of 2025, despite a 4.91% decline in revenue [4] - Haisheng Pharmaceutical achieved a 40.89% increase in revenue and a 47.16% increase in net profit for the first three quarters of 2025 [5] Capital Market Activities - New Tian Di has entered a strategic cooperation agreement with Nanjing Zhihe Pharmaceutical to develop GLP-1 long-acting peptide innovative drugs [6][7] - WuXi AppTec signed strategic cooperation memorandums with NEOM and the Saudi Ministry of Health to explore localized new drug R&D and production services [8] Industry Events - The results of the 11th batch of national drug centralized procurement were announced, including 55 drugs aimed at stabilizing clinical needs and ensuring quality [9][10] - The procurement process has raised the qualification thresholds for bidding companies and aims to prevent collusion in pricing [10] Intellectual Property Developments - The Deputy Director of the National Intellectual Property Administration of China met with representatives from the International Pharmaceutical Alliance to discuss patent protection and dispute resolution mechanisms [11] Shareholder Actions - BioVeda, a major shareholder of AoJing Medical, has completed a share reduction plan, selling 1.3555 million shares, which represents 1% of the company's total equity [12]

Group 1 - Shanghai Pharmaceuticals has received approval for the production of Bromperidol Sustained-Release Tablets from the National Medical Products Administration [1][2] - The drug is classified as a Class 3 chemical drug with a specification of 0.18g per tablet and has been registered under the approval number H20255730 [2] - The drug is indicated for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1959 [3] Group 2 - As of the announcement date, no other companies in China have listed Bromperidol Sustained-Release Tablets [4] - According to IQVIA data, the procurement amount for Bromperidol Tablets in hospitals in mainland China is approximately RMB 60.29 million for 2024 [5] - The company has invested approximately RMB 16.009 million in research and development for this drug [3] Group 3 - The approval of the drug is expected to enhance the market share and competitiveness of Shanghai Pharmaceuticals, benefiting from national policies that support newly registered generic drugs in medical insurance and procurement [6] - The company aims to leverage this experience for future generic drug applications [6]